Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol in advanced solid tumors
NCT02013492Phase 1Completed
- Start
- Jan 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of propranolol in solid tumor. Primary endpoints: Incidence of toxicity graded according to Common Terminology Criteria for Adverse Events (CTCAE) V. 4.0 up to 4 months, Change in vascular endothelial growth factor (VEGF) at 4 months and 2 more. Started Jan 2014; status: completed.
02
Drugs
propranolol
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02013492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02013492.